Skip to main content
Download PDF

A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease

BMC Complementary Medicine and Therapies volume 24, Article number: 151 (2024) Cite this article

Abstract

Aims

Sodium tanshinone IIA sulfonate (STS) injection has been widely used as adjunctive therapy for pulmonary heart disease (PHD) in China. Nevertheless, the efficacy of STS injection has not been systematically evaluated so far. Hence, the efficacy of STS injection as adjunctive therapy for PHD was explored in this study.

Methods

Randomized controlled trials (RCTs) were screened from China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang Database, PubMed, Sino-Med, Google Scholar, Medline, Chinese Biomedical Literature Database, Cochrane Library, Embase and Chinese Science Citation Database until 20 January 2024. Literature searching, data collection and quality assessment were independently performed by two investigators. The extracted data was analyzed with RevMan 5.4 and STATA 14.0. Basing on the methodological quality, dosage of STS injection, control group measures and intervention time, sensitivity analysis and subgroup analysis were performed.

Results

19 RCTs with 1739 patients were included in this study. Results showed that as adjunctive therapy, STS injection combined with Western medicine showed better therapeutic efficacy than Western medicine alone for PHD by increasing the clinical effective rate (RR = 1.22; 95% CI, 1.17 to 1.27; p < 0.001), partial pressure of oxygen (MD = 10.16; 95% CI, 5.07 to 15.24; p < 0.001), left ventricular ejection fraction (MD = 8.66; 95% CI, 6.14 to 11.18; p < 0.001) and stroke volume (MD = 13.10; 95% CI, 11.83 to 14.38; p < 0.001), meanwhile decreasing the low shear blood viscosity (MD = -1.16; 95% CI, -1.57 to -0.74; p < 0.001), high shear blood viscosity (MD = -0.64; 95% CI, -0.86 to -0.42; p < 0.001), plasma viscosity (MD = -0.23; 95% CI, -0.30 to -0.17; p < 0.001), hematokrit (MD = -8.52; 95% CI, -11.06 to -5.98; p < 0.001), fibrinogen (MD = -0.62; 95% CI, -0.87 to -0.37; p < 0.001) and partial pressure of carbon dioxide (MD = -8.56; 95% CI, -12.09 to -5.02; p < 0.001).

Conclusion

STS injection as adjunctive therapy seemed to be more effective than Western medicine alone for PHD. However, due to low quality of the included RCTs, more well-designed RCTs were necessary to verify the efficacy of STS injection.

Peer Review reports

Introduction

Pulmonary heart disease (PHD) is considered to be caused by lesions in lung and bronchial tissue, as well as the pulmonary vascular system [1]. It was reported that PHD accounted for 10–30% of all heart failure patients and over 40% of chronic lung disease patients had the signs of PHD at autopsy in United states [2, 3]. Nowadays, many Western medicines have been successfully employed to treat PHD, including vasodilators, antibiotics, diuretics, etc. However, the clinical efficacy of these Western medicines is usually unsatisfactory [4]. Recently, a large number of researches showed that traditional Chinese medicine (TCM) had positive therapeutic effects in the treatment of PHD [5,6,7,8,9,10].

Sodium tanshinone IIA sulfonate (STS) injection is the water-soluble derivative of tanshinone IIA and the chemical structure is shown in Fig S1[11]. STS is a pharmacologically active compound extracted from traditional Chinese medicine named as Danshen [12, 13]. STS injection is usually diluted with 5% glucose injection of 250 or 500 mL and then given to the PHD patients through intravenous drip (once a day). It was reported that STS injection also showed great potential in treating stroke, pulmonary diseases, hepatic diseases and sepsis [11]. Recent studies showed that STS injection could inhibit proliferation of pulmonary smooth muscle cells and stimulate expression of Kv2.1 [14], as well as suppress the expression of canonical transient receptor pulmonary arterial smooth muscle cells derived from the rat model of pulmonary hypertension [15]. Moreover, STS injection could inhibit hypoxia-induced enhancement of store-operated calcium entry (SOCE) in pulmonary arterial smooth muscle cells via activation of the PKG-PPAR-γ signaling axis [13].

Currently, a great deal of studies has reported that STS injection combined with Western medicine has great potentials in the treatment of PHD with positive results. As far as we know, neither systematic review nor meta-analysis about the efficacy of STS injection as adjunctive therapy for treating PHD has yet been reported. Hence, the aim of this study is to summarize the available evidence from the published randomized controlled trials (RCTs) to demonstrate the efficacy of STS injection as adjunctive therapy for PHD with a comprehensive PRISMA-compliant systematic review and meta-analysis [16,17,18,19,20,21].

Methods

Inclusion criteria

Two investigators (H.K. Shao and D.S. Xu) independently searched and screened the eligible RCTs according to the PICOS principle: (1) Patients (P): The study population was the PHD patients which met with the diagnostic criteria for chronic PHD of China or the World Health Organization (WHO) diagnostic criteria for PHD. (2) Intervention (I): STS injection combined with Western medicine was given to the PHD patients in the treatment group. (3) Comparisons (C): Western medicine alone was given to the PHD patients in the control group. (4) Outcomes (O): clinical effective rate was selected as the primary outcome in this study; partial pressure of oxygen (PaO2), left ventricular ejection fraction (LVEF), stroke volume (SV), low shear blood viscosity (LBV), plasma viscosity (PV), high shear blood viscosity (HBV), hematokrit (HCT), fibrinogen (FIB), partial pressure of carbon dioxide (PaCO2) and adverse reactions were chosen as the secondary outcomes. (5) Study design (S): the included studies should be randomized controlled trials (RCTs).

Exclusion criteria

RCTs should be removed from this meta-analysis when they could not satisfy the above inclusion criteria and: (1) In the treatment or control group, the formulation and dosages of interventions were not provided; (2) Incomplete data in the RCTs or repeated publications were found; (3) Other Chinese herb medicine was used in the RCT; (4) Type of articles was meeting abstracts, case reports and literature reviews; (5) Obvious data obfuscations and wrong data were found.

Information sources

To screen the eligible RCTs, many databases including Google Scholar, China National Knowledge Infrastructure (CNKI), PubMed, Medline, Wanfang Database, China Science and Technology Journal Database (VIP), Embase, Sino-Med, Chinese Biomedical Literature Database, Cochrane Library and Chinese Science Citation Database were systematically searched. The nearest update for the RCTs was performed on 20 January 2024.

Search strategies

To select the eligible RCTs, the following keywords in English databases were searched and scanned by joint or separate method: STS injection, STS, PHD and cor pulmonale. The following keywords in Chinese databases were searched and scanned by joint or separate method as follows: Danshentong IIA, Danshentong IIA Huangsuanna Zhusheye [STS injection], Danshentong IIA huangsuanna [Sodium tanshinone IIA sulfonate], Feixinbing [PHD or cor pulmonale] and Feiyuanxingxinzangbing [PHD or cor pulmonale]. In addition, the references in the included RCTs were read to obtain the eligible RCTs.

Study selection

To obtain the included RCTs, the above databases were systematic searched by two investigators (H.K. Shao and D.S. Xu) according to the inclusion and exclusion criteria. Any dispute in the process of study selection was solved by discussion with a third investigator (L.G. Zhao).

Data collection process

Full text of the included RCTs was carefully read by one investigator (H.K. Shao) and the relevant data was extracted at the same time. Another investigator (D.S. Xu) verified the completeness and accuracy of the collected data. Any disputes during the process of data collection were solved by discussion with a third investigator (L.G. Zhao). To analyze the extracted data, the software STATA 14.0 (Stata Corp LLC, Texas, USA) and Review Manager 5.4 (Cochrane Collaboration, Nordic Cochrane center, Copenhagen, Denmark) were employed in this meta-analysis.

Data items

One investigator (H.K. Shao) collected the following data items from the included RCTs: (a) First author’s name; (b) Sample size of the patients; (c) Publication date; (d) Interventions in the treatment group and control group; (e) Outcome measures; (f) Duration of interventions; (g) Adverse reactions. The accuracy and completeness of data items were carefully checked by another investigator (D.S. Xu).

Quality assessment

Methodological qualities of the included RCT were evaluated with Jadad scoring system and it was ranged from 0 to 5 scores (Table S1) [17,18,19,20,21,22]. According to the items of randomization, withdrawals (dropouts) and blinding, the methodological qualities were independently assessed by two investigators (H.K. Shao and D.S. Xu). Scores were given to the included RCTs if they meet with the following criteria: Method of randomization was provided, 1 score; suitable randomization method was given, 1 score; withdrawals and dropouts were given, 1 score; double blinding method was given, 1 score; suitable double-blinding method was given, 1 score. RCT obtained 1 or 2 scores was considered as the low-quality study and 3 to 5 scores was considered as high-quality study [17,18,19,20,21]. A third investigator (L.G. Zhao) was involved to solve the disputes in the process of quality assessment. The risk of bias was independently evaluated by two investigators using the Cochrane risk of bias (ROB) tool. Seven aspects including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias were included in the ROB tool and each aspect was divided into “low risk”,“high risk” and “unclear risk”. Disagreements in the evaluation of the risk of bias were resolved by discussions with the third investigator (L.G. Zhao) [23].

Statistical analysis

Statistical analysis in this meta-analysis was conducted using the software RevMan 5.4. Dichotomous variables were expressed as the pooled risk ratios (RR) with 95% confidence interval (CI), whereas continuous variables were expressed as the weighted mean difference (MD) with 95% CI. To assess the heterogeneity among the RCTs, Chi-squared test and I2 statistic were used. If I2 > 50% or p < 0.05, it indicated that there was significant heterogeneity and we should use random-effect model to assess the data. If not, the fixed-effect model should be chosen. Z-test was adopted to estimate whether the overall effect of STS injection combined with Western medicine was better than Western medicine alone for PHD. It suggested that significant statistical difference was observed when p < 0.05 [23, 24]. Meta-regression was performed to investigate whether the potential presence of effect modifiers explained any of the heterogeneity of treatment effects of STS injection between RCTs. In this study, meta-regression was conducted basing on the following variables: STS injection dosage, control group measures and intervention time. Significant differences were considered if p < 0.05.

Sensitivity and subgroup analysis

Sensitivity analysis was performed to estimate the impact of the included RCTs with low-quality on the overall effects of STS injection for PHD basing on the Jadad scoring system. To assess if the overall effect was homogeneous within subgroups, subgroup analysis was performed basing on the dosage of STS injection (the subgroups with specific dosage and a dynamic range dosage), control group measures (the subgroups with only enalapril and other medicines) and intervention time.

Risk of bias across studies

To obtain accuracy results for the publication bias, Egger’s test and Begg’s test were also conducted.

Results

Study selection process

As shown in Fig. 1, the study selection process was described. At the beginning, 3337 potential studies were identified from the databases. Due to the duplications, animal experiments and literature reviews, 3010 studies were excluded according to the eligible criteria. Full texts of 327 studies were downloaded and carefully read basing on the inclusion criteria. Finally, a total of 19 RCTs were chosen for the methodological quality evaluation and further meta-analysis.

Fig. 1
figure 1

PRISMA flow diagram of study selection process. CNKI is China National Knowledge Infrastructure; VIP is Chinese Scientific Journal Database; WF is Wangfang Data; Other sources are Google Scholar, Medline, Sino-Med, Chinese Biomedical Literature Database, Chinese Science Citation Database, Cochrane Library and Embase

Full size image

Study characteristics

Table 1 presented the features of the included 19 RCTs. All the RCTs were reported on Chinese journals and the date of publication ranged from 2011 to 2021 [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43]. The sample size of the PHD patients was from 44 to 146 with 1739 patients in all and the average value was 91.53. Duration of intervention for treating PHD was 10 days at least, 14 days mostly. For the control group, several kinds of conventional Western medicine were given, including phentolamine mesylate injection, sodium nitroprusside, enalapril, meglumine adensine cyclphsphate injection, aminophylline, salbutamol, roxithromycin, ceftazidime, alprostadil and sildenafil. Basing on the control group, different dosage of STS injection from 40 to 80 mg (once a day) were employed in the treatment group. Among the included 19 RCTs, clinical effective rate was chosen as the therapeutic indicator in 18 RCTs. There were 6 RCTs that reported LBV and/or HBV as the outcomes. PV was chosen as the outcome by 12 RCTs. There were 8 RCTs reported HCT as their outcome measure. FIB was chosen as the outcome measure by 7 RCTs. The outcome measure PaO2 was selected by 5 RCTs and LVEF was reported by 6 RCTs. SV was elected as outcome measure by 5 RCTs. Moreover, there were 4 RCTs that reported PaCO2 as their outcome measures.

Table 1 Characteristics of RCTs on STS injection for PHD
Full size table

Risk of bias in individual studies

In this study, Jadad score was employed to estimate the methodological quality. As described in Tables 2 and 8 RCTs obtained 3 scores, 7 RCTs acquired 2 scores, the rest of 4 RCTs acquired 1 score, indicating that there were 8 high-quality RCTs and 11 low-quality RCTs.

Table 2 Quality of the included RCTs
Full size table

Clinical effective rate

Clinical effective rate was chosen as the outcome by 18 RCTs. The clinical effective rate referred to the ratio of the responders to total PHD patients. The definition of responder was based on efficacy criteria of the Chinese National Conference on Cor Pulmonale in the years of 1977/1980 and an improvement of at least one class in the cardiopulmonary function was defined as the efficacy criteria. The calculation formula was defined as follows: (the number of remarkable recovery patients + the number of improved recovery patients)/total number of PHD patients × 100%. The efficacy was divided into three levels: ineffective, improved recovery and remarkable recovery. If the clinical symptoms were completely ameliorated and the cardiac function was improved by two levels, it could be considered as a remarkable recovery. For improved recovery, relief from clinical symptoms and an improvement in cardiac function by one level appeared in PHD patients. As depicted in Fig. 2, since there was no heterogeneity (p = 1.00, I2 = 0%), the fixed-effect model was used to analyze the collected data. The pooled RR value was 1.22 (95% CI, 1.17 to 1.27; Z = 9.05, p < 0.001), indicating that as an adjunctive therapy, STS injection combined with Western medicine had better therapeutic efficacy in treating PHD than Western medicine alone. To provide an accuracy result for publication bias, Begg’s test and Egger’s test were introduced. Results from Begg’s test (Z = 3.26, p = 0.001) and Egger’s test (t = 6.18, p = 0) also suggested that there was publication bias. Sensitivity analysis was performed to assess the influence of low-quality RCTs on the overall effects of STS injection combined with Western medicine. No significant difference was detected when the lower-quality RCTs were gradually excluded as shown in Table 3. There were little changes (0.01 in magnitude) between the RCTs with high-quality (Jadad scores ≥ 3) and that with low-quality (Jadad scores < 3). Subgroup analysis based on STS injection dosage (the subgroups with specific dosage and a dynamic range dosage), control group measures (the subgroups with only enalapril and other medicines) and intervention time (the subgroups with intervention time less than or more than 14 days) indicated that there was no difference between these factors, consistently demonstrating that STS injection could improve the efficacy for PHD.

Fig. 2
figure 2

Forest plot of the clinical effective rate of STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image
Table 3 Sensitivity and subgroups analysis based on clinical effective rate
Full size table

LBV

As shown in Fig. 3, six RCTs reported LBV as their outcome measure. Owing to the high heterogeneity (p = 0.001, I2 = 75%) among the six RCTs, the random effect model was selected. In comparison with Western medicine alone, the results indicated that STS injection as an adjunctive therapy can decrease the LBV (MD = -1.16; 95% CI, -1.57 to -0.74; p < 0.001). As shown in Table S2, sensitivity analysis demonstrated that the results were robust. Due to the large heterogeneity in the included studies, subgroup analysis was performed basing on STS injection dosage, control group measures and intervention time. However, results from subgroup analysis showed that these parameters had no significant interaction. In addition, Egger’s test (t = 0.21, p = 0.847) and Begg’s test (Z = 0, p = 1.00) were performed and the results indicated that there was no publication bias among the six RCTs.

Fig. 3
figure 3

Forest plot of LBV on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

HBV

The outcome HBV was selected as the therapeutic indicator by six RCTs. The random effect model was selected because of significant heterogeneity (p < 0.001, I2 = 90%). As shown in Fig. 4, STS injection as adjunctive therapy had more power in decreasing the level of HBV comparing with Western medicine alone (MD = -0.64; 95% CI, -0.86 to -0.42; p < 0.001). As shown in Table S3, sensitivity analysis demonstrated that the results were robust. Due to the large heterogeneity in the included studies, subgroup analysis was performed basing on STS injection dosage, control group measures and intervention time. However, results from subgroup analysis showed that these parameters had no significant interaction. To evaluate the publication bias, Egger’s test (t = -0.68, p = 0.533) and Begg’s test (Z = 0, p = 1.00) were performed and results indicated that there was no publication bias within the six RCTs.

Fig. 4
figure 4

Forest plot of HBV on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

PV

The outcome PV was reported by twelve RCTs and the results were expressed in Fig. 5. Since significant heterogeneity (p < 0.001, I2 = 88%) was found, the random effect model was selected for analyzing the collected data. Compared with Western medicine alone, the adjunctive use of STS injection seemed more effective in decreasing PV (MD = -0.23; 95% CI, -0.30 to -0.17; p < 0.001). As shown in Table S4, robust results were found in the process of sensitivity analysis. Owing to the large heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. Results from subgroup analysis showed that these parameters had no significant interaction. Moreover, results from Egger’s test (t = 0.53, p = 0.606) and Begg’s test (Z = 0.21, p = 0.837) indicated that no publication bias was observed among the thirteen RCTs.

Fig. 5
figure 5

Forest plot of PV on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

HCT

There were 8 RCTs involving 726 patients that reported HCT as the outcome measure. In Fig. 6, we could find that random effect model was used to analyze the data because of significant heterogeneity (p < 0.001, I2 = 95%). This result demonstrated that STS injection as adjunctive therapy had better effects in decreasing HCT comparing with using Western medicine alone (MD = -8.52; 95% CI, -11.06 to -5.98; p < 0.001). As shown in Table S5, robust results were found in the process of sensitivity analysis. Owing to the large heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. Results from subgroup analysis showed that these parameters had no significant interaction. To prove if there was potential publication bias, Egger’s test (t = 0.98, p = 0.364) and Begg’s test (Z = 0.87, p = 0.386) were performed and results indicated that there was no publication bias among the eight RCTs.

Fig. 6
figure 6

Forest plot of HCT on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

FIB

FIB was reported in seven RCTs. There was high heterogeneity among these eight RCTs (p < 0.001, I2 = 94%) and the random effect model was conducted in this meta-analysis. As shown in Fig. 7, the overall MD of FIB was − 0.62 (95% CI, -0.87 to -0.37; p < 0.001) among the eight RCTs, indicating that STS injection combined with Western medicine was more effective in decreasing FIB than Western medicine alone. In Table S6, results from sensitivity analysis were robust. Owing to the large heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. Results from subgroup analysis showed that these parameters had no significant interaction. In addition, Egger’s test (t = -0.79, p = 0.467) and Begg’s test (Z = 0.60, p = 0.548) were carried out to detect the potential publication bias and results indicated that there was no publication bias.

Fig. 7
figure 7

Forest plot of FIB on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

PaO2

PaO2 was selected as the outcome measure by five RCTs. The random effect model was adopted since a high heterogeneity within the 5 RCTs (p < 0.001, I2 = 90%) was detected. As shown in Fig. 8, the overall MD for PaO2 was 10.16 (95% CI, 5.07 to 15.24; p < 0.001) within the included 5 RCTs, which demonstrated that STS injection as adjunctive therapy presented better effect in increasing the level of PaO2 than Western medicine alone. Table S7 indicated that results of sensitivity analysis were robust. Owing to the large heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. Results from subgroup analysis showed that the large heterogeneity could be attributed to the inconsistency of control group measures in the included studies. In the 5 RCTs, only enalapril was used for control group measures in one RCTs and the rest of four RCTs selected other medicines including phentolamine mesylate injection, meglumine adensine cyclphsphate injection, alprostadil and sildenafil. Different control group measures might cause the large heterogeneity. To estimate the publication bias for the 5 included RCTs, Egger’s test (t = 1.59, p = 0.21) and Begg’s test (Z = 0.24, p = 0.806) were employed in this study. According to the results, no publication bias was found.

Fig. 8
figure 8

Forest plot of PaO2 on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

PaCO2

Four RCTs with 379 patients provided data for PaCO2. As shown in Fig. 9, STS injection combined with Western medicine could significantly reduce PaCO2 for the PHD patients (MD = -8.56; 95% CI, -12.09 to -5.02; p < 0.001). In this meta-analysis, a random effect model was used since there was a high heterogeneity (p = 0.0003, I2 = 84%) among these four RCTs. Table S8 indicated that results of sensitivity analysis were robust. Owing to the large heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. However, results from subgroup analysis showed that the large heterogeneity could be attributed to the inconsistency of STS injection dosage in the included studies. Publication bias for the included RCTs was evaluated by STATA 14.0 with Begg’s test and Egger’s test. Evidence from Egger’s test (t = 1.19, p = 0.357) and Begg’s test (Z = 0.34, p = 0.734) proved that no publication bias was detected.

Fig. 9
figure 9

Forest plot of PaCO2 on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

LVEF

Six RCTs provided the therapeutic indicator LVEF as the outcome measure. In Fig. 10, we could find that a significant heterogeneity (p < 0.001, I2 = 86%) emerged and the random effect model was adopted. Moreover, it was obvious to find that the efficacy of STS injection as adjunctive therapy was more effective in increasing LVEF for the PHD patients than Western medicine alone (MD = 8.66; 95% CI, 6.14 to 11.18; p < 0.001). In Table S9, we could observe that there was big difference between the low-quality (Jadad score < 3) and high-quality (Jadad score ≥ 3) RCTs from results of sensitivity analysis. Besides, subgroup analysis basing on STS injection dosage, control group measures and intervention time was performed and results showed that the large heterogeneity could be attributed to the inconsistency of STS injection dosage, control group measures and intervention time among the included studies. Hence, publication bias among the six RCTs was evaluated with Egger’s test and Begg’s test. The evidence from Egger’s test (t = -0.47, p = 0.66) and Begg’s test (Z = 0, p = 1.00) showed that publication bias might exist within the seven RCTs.

Fig. 10
figure 10

Forest plot of LVEF on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

SV

The outcome SV was reported by five RCTs. The results of meta-analysis were shown in Fig. 11 and it could be observed that a moderate heterogeneity (p = 0.10, I2 = 49%) existed. Hence, the fixed effect model was selected. Results from this meta-analysis (MD = 13.10; 95% CI, 11.83 to 14.38; p < 0.001) demonstrated that STS injection as adjunctive therapy displayed better effect in increasing SV than Western medicine alone. As shown in Table S10, robust results were found in the process of sensitivity analysis. Owing to the slight heterogeneity within the included studies, subgroup analysis was conducted basing on STS injection dosage, control group measures and intervention time. Results from subgroup analysis showed that these parameters had no significant interaction, consistently supporting the therapeutic efficacy of STS injection as adjunctive therapy. Publication bias had also been evaluated for the five RCTs and results from Egger’s test (t = -0.64, p = 0.57) and Begg’s test (Z = 0.73, p = 0.462) suggested that there was no publication bias within the 5 RCTs.

Fig. 11
figure 11

Forest plot of SV on STS injection as adjunctive therapy vs. Western medicine alone for PHD. STS is sodium tanshinone IIA sulfonate injection and WM is Western medicine

Full size image

Risk of bias assessment

In Fig. 12, the risk of bias graph of the included 19 RCTs was described. Almost all RCTs reported random sequence generation, but only 8 RCTs reported the specific randomization methods [28,29,30, 34, 36, 40,41,42]. All RCTs did not report allocation concealment, blinding of outcome assessment, blinding of participants and personnel, so they were evaluated as “unclear risk”. All outcome data were complete, therefore it was considered that there was no risk of incomplete outcome data. No selective reporting was identified and they were considered as “low risk”. Moreover, none of the included RCTs mentioned any other sources of bias, so our study considered that there was no other bias risks.

Fig. 12
figure 12

Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies

Full size image

Meta-regression

Meta-regression between the adjunctive therapy of STS injection and using Western medicines alone for PHD in improvement of clinical effective rate, the level of LBV, HBV, PV, HCT, FIB, PaO2, PaCO2, LVEF and SV based on STS injection dosage, control group measures and intervention time were performed. However, no obvious significant difference was found in the Table S11 (most of p value was more than 0.05).

Adverse reaction

As shown in Table 4, seven RCTs provided the adverse reactions and other thirteen RCTs did not report. Besides, it could be seen that using Western medicine alone could cause rhinobyon, orthostatic hypotension, tachycardia, dry cough, hypotension, abnormal liver function, urticaria, fever, gastrointestinal reaction, nausea and vomiting for the PHD patients. Similar to the control group, the adverse reactions including rhinobyon, orthostatic hypotension, dry cough, hypotension, abnormal liver function, urticaria, fever, gastrointestinal reaction, nausea and vomiting also existed in the treatment group (STS injection combined with Western medicine). Nevertheless, no serious adverse event was reported in these two groups. In the treatment group, the incidence rate of adverse reaction was 2.31% (21/909), while it was 2.21% (20/906) in the control group. No obvious difference (RR = 1.05; 95% CI, 0.57 to 1.92; Z = 0.15, p = 0.88) was observed after analyzing the incidence rates with RevMan 5.4.

Table 4 Incidence rate of adverse reaction
Full size table

Discussion

Previously, some studies on the systematic review or meta-analysis of TCM as adjunctive therapy for PHD were conducted with positive results. Liu et al. conducted a systematic review and meta-analysis involving 35 RCTs with 2715 patients for assessing the efficacy and safety of salvia miltiorrhiza injection on PHD [5]. In their results, they found that conventional medicine treatment in combination with salvia miltiorrhiza or complex salvia miltiorrhiza injection displayed better effects in improving clinical effectiveness rates, PaO2 and hemorheology, meanwhile decreasing PaCO2 and alleviating mPAP compared with routine medicine treatment alone. Although nice results were concluded by them, several limitations still existed in their work. Firstly, significant heterogeneity was detected among the included RCTs. However, they did not perform the sensitive analysis and subgroup analysis in the study, which could cause an inaccuracy result for the efficacy of salvia miltiorrhiza injection. Secondly, only funnel plot was adopted for evaluating publication bias, which could not offer an accuracy result. Thirdly, their work did not follow the PRISMA-guideline, which made the conclusion unreliable. Li et al. conceived another systematic review and meta-analysis for a famous TCM injection (ligustrazine injection) for the treatment of PHD [44]. In their work, they found that ligustrazine injection might be a promising treatment method for PHD since the adjunctive use of ligustrazine injection had better effect in improving the NYHA clinical status (New York Heart Association classification, NYHA) and depression of pulmonary artery hypertension than Western medicine alone. But only four therapeutic indicators were employed for the meta-analysis in their work, which might cause the overestimation or underestimation for ligustrazine injection in the treatment of PHD. Besides, publication bias, sensitive analysis and subgroup analysis also had not been performed by them. Li et al. demonstrated the potential therapeutic effectiveness of shenmai injection combined with conventional medical treatment for PHD [45]. Thirty-three RCTs with 2617 patients were involved in their meta-analysis and it was based on six outcome measures including death, adverse events, NYHA clinical status, hemodynamics, PaO2, PaCO2. However, as the same reason to the above two studies, sensitive analysis and subgroup analysis were also ignored, which might not be enough to obtain a reliable result on the efficacy of shenmai injection. Many different shortcomings existed in the previous systematic review or meta-analysis for evaluating the adjunctive therapy of TCM for PHD.

PHD is becoming a major problem to menace people’s health and life quality. Recently, many studies showed that STS injection as adjunctive therapy had positive therapeutic effects for PHD. Therefore, this study aimed to demonstrate the efficacy of STS injection as adjunctive therapy for PHD and it was strictly reported according to the PRISMA statement with the items of subgroup analysis, sensitive analysis and publication bias evaluation, which was more comprehensive than previous studies (Table S12). Results showed that STS injection as adjunctive therapy displayed better therapeutic effect than Western medicine alone for the improvement of the clinical effective rate (RR = 1.22; 95% CI, 1.17 to 1.27; p < 0.001). Moreover, meta-analysis basing on other outcome measures including PaO2, LVEF, SV, LBV, HBV, PV, HCT, FIB and PaCO2 also consistently demonstrated the good therapeutic efficacy of STS injection as adjunctive therapy for PHD. Moreover, this meta-analysis showed that the incidence rate of adverse reactions in the control group seemed slightly lower than that of the treatment group. However, results from this study proved that it had no difference between these two groups. Besides, there was no RCT reported serious adverse reactions. On the whole, we could conclude that it was safe when using STS injection for treating PHD.

Previous studies have revealed that STS could decrease mean pulmonary arterial pressure, pulmonary arterial thickness, mean right ventricular pressure, right ventricular hypertrophy index and the right ventricular systolic pressure for hypoxia or monocrotaline induced pulmonary hypertension model in rat. The mechanisms could be attributed to STS in controlling the expression of transient receptor potential canonical proteins, PPAR-γ and Kv2.1 of pulmonary artery. The underlying mechanisms also could be attributed to STS in suppressing Ca2+ entry and PKG-PPAR-γ signaling pathway [13, 14]. The definition of PHD is right ventricular failure secondary to pulmonary hypertension and it was caused by pulmonary vascular disease or chronic obstructive pulmonary disease (COPD). Through controlling the signaling pathway of MAPK/HIF-1alpha, STS could reduce many inflammatory cytokines in cigarette smoke-induced COPD mice, such as TNF-α and IL-6 [46, 47]. Moreover, the increase of PaO2, LVEF, SV and decrease of LBV, HBV, PV, HCT, FIB and PaCO2 in this meta-analysis could be the valid evidence to demonstrate the good efficacy of STS injection as adjunctive therapy in treating PHD.

Although great potentials of STS injection for the treatment of PHD were well demonstrated in this study, several limitations still existed. Firstly, the methodological quality of some RCTs was lower than three scores, indicating the poor quality. Method of randomization was rarely described in some included RCTs, which was the main reason to cause the low-quality RCTs. Hence, to reduce the selection bias, randomization method should be described in the included RCTs. Secondly, in many included RCTs, blinding for investigators or patients had not been provided, which could lead to an inaccurate evaluation for STS injection. Thirdly, the heterogeneity was large and it could be attributed to the inconsistency of dosage, control group measures and intervention time in the included RCTs. Moreover, the current research is not registered and there may be a small deviation, but this study still strictly follow the steps of systematic evaluation (Meta-analysis).

Although the advantages of STS injection as adjunctive therapy for PHD have been well demonstrated in this study, evidence was still lacking owing to the low quality within the included RCTs. Therefore, several recommendations were given to the future RCTs on STS injection for PHD. Firstly, the future designed RCTs should strictly meet with the consolidated standards of reporting trials statement (CONSORT 2010). Secondly, to offer reliable evidences for STS injection, more RCTs with multicentre and high-quality are highly recommended.

Conclusion

Our study has demonstrated that as adjunctive therapy, STS injection combined with Western medicine seemed to be more effective than Western medicine alone for PHD with available evidences. Nevertheless, owe to the low methodological quality of included RCTs, more RCTs with higher quality were highly recommended to verify the effects of STS injection for PHD.

Data availability

The data underlying this article are available in the article and its online supplementary materials.

Abbreviations

CI:

Confidence interval

CNKI:

China National Knowledge Infrastructure

COPD:

Chronic obstructive pulmonary disease

FIB:

Fibrinogen

HBV:

High shear blood viscosity

LBV:

Low shear blood viscosity

LVEF:

Left ventricular ejection fraction

MD:

Mean difference

PaCO2 :

Partial pressure of carbon dioxide

PaO2 :

Partial pressure of oxygen

PHD:

Pulmonary heart disease

PV:

Plasma viscosity

RCTs:

Randomized controlled trials

RR:

Risk ratios

SOCE:

Store-operated calcium entry

STS:

Sodium tanshinone IIA sulfonate

SV:

Stroke volume

TCM:

Traditional Chinese medicine

VIP:

China Science and Technology Journal Database

WHO:

World health organization

References

  1. Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circul. 2013;3(1):5–19.

    Article  CAS  Google Scholar 

  2. Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003;24(3):233–44.

    Article  PubMed  Google Scholar 

  3. Wang KH, Wu JR, Wang HJ, Duan XJ, Zhang D, Wang YZ, Ni MW, Liu SY, Meng ZQ, Zeng XT, Zhang XM. Comparative efficacy of Chinese herbal injections for pulmonary heart disease: a bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11:634.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Qiu J, Guo YJ, Yue HM, Yang YP. Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. Bioscience Rep. 2020;40(3):BSR20200099.

    Article  CAS  Google Scholar 

  5. Liu Y, Huang YH, Zhao CY, Qin XD, Zhu QH, Chen S, Qu JL. Salvia miltiorrhiza injection on pulmonary heart disease: a systematic review and meta-analysis. Am J Chin Med. 2014;42(6):1315–31.

    Article  PubMed  Google Scholar 

  6. Shi LW, Xie YM, Liao X, Chai Y, Luo YH. Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: a systematic review and meta-analysis of randomized controlled trials. BMC Complem Altern Med. 2015;15:418.

    Article  Google Scholar 

  7. Hu XY, Li LL, Song YY, Lu Y. Effectiveness and safety of traditional Chinese medicines for pulmonary heart disease. Medicine. 2021;100(1):e24131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xiong C, Li Y, Zhuang GT, Zeng Y, Wei H, Li CY, Li L, Li L, Fu JJ. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med. 2021;59:102691.

    Article  PubMed  Google Scholar 

  9. Li L, Yang DL, Li JH, Niu L, Chen Y, Zhao X, Oduro PK, Wei C, Xu ZP, Wang QL, Li YH. Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation. BMC Complement Med Ther. 2020;20:112.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hong ML, Hong CL, Chen HN, Ke GS, Huang JR, Huang XH, Liu YH, Li FS, Li CD. Effects of the Chinese herb formula yufeining on stable chronic obstructive pulmonary disease. Medicine. 2018;97:39e12461.

    Article  Google Scholar 

  11. Zhou ZY, Zhao WR, Zhang J, Chen XL, Tang JY. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother. 2019;118:109362.

    Article  CAS  PubMed  Google Scholar 

  12. Shang QH, Xu H, Huang L. Tanshinone IIA: a promising natural cardioprotective agent. Evid Based Complement Alternat Med. 2012;2012:716459.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jiang Q, Lu W, Yang K, Hadadi C, Fu X, Chen Y. Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-gamma signaling axis. Am J Physiol Cell Physiol. 2016;311:136–49.

    Article  Google Scholar 

  14. Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, Gao YQ, Li ZC. Effects of sodium tanshinone IIA sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol. 2009;125(3):436–43.

    Article  CAS  PubMed  Google Scholar 

  15. Wang J, Jiang Q, Wan LM, Yang K, Zhang Y, Chen YQ, Wang E, Lai N, Zhao L, Jiang H, Sun YQ, Zhong NS, Ran PX, Lu WJ. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol. 2013;48:125–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyzes: the PRISMA Statement. PLoS Med. 2009;6(6):e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Shao HK, Huang Y, Xu DS, Huang SF, Tong RS. A systematic review and meta-analysis on the efficacy of puerarin injection as adjunctive therapy for unstable angina pectoris. Front Cardiovasc Med. 2022;9:763567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shao HK, Fang CY, Huang Y, Ye YL, Tong RS. Sodium tanshinone IIA sulfonate injection as adjunctive therapy for the treatment of heart failure: a systematic review and meta-analysis. Phytomedicine. 2022;95:153879.

    Article  CAS  PubMed  Google Scholar 

  19. Shao HK, He X, Zhang LJ, Du S, Yi XQ, Cui XJ, Liu XX, Huang SF, Tong RS. Efficacy of ligustrazine injection as adjunctive therapy in treating acute cerebral infarction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:761722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Shao HK, Li MS, Chen FC, Chen LH, Jiang ZJ, Zhao LG. The efficacy of Danshen injection as adjunctive therapy in treating angina pectoris: a systematic review and meta-analysis. Heart Lung Circ. 2018;27:433–42.

    Article  PubMed  Google Scholar 

  21. Shao HK, Zhao LG, Chen FC, Zeng SB, Liu SQ, Li JJ. Efficacy of ligustrazine injection as adjunctive therapy for angina pectoris: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3704–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  23. Wang KH, Wu JR, Zhang D, Duan XJ, Ni MW. Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis. BMC Complement Med Ther. 2018;18:41.

    Article  Google Scholar 

  24. Lin HY, Wan MY, Ye Y, Zheng GH. Effects of Baduanjin exercise on the physical function of middle-aged and elderly people: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2020;23:38.

    Article  Google Scholar 

  25. Chai YQ, Wu YM. Clinical observation of Tanshinone IIA sulfonate sodium injection combined with phentolamine in treatment of acute exacerbation of pulmonary heart disease. Drugs Clin. 2017;32(11):2124–8. (In Chinese).

    Google Scholar 

  26. Cheng KF. Clinical observation of 60 cases of chronic pulmonary heart disease with heart failure treated by sodium nitroprusside combined with sodium tanshinone IIA sulfonate. J Clin Med. 2017;4(12):2355–7. (In Chinese).

    Google Scholar 

  27. Chen JX. Clinical observation of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jilin Med. 2016;37(6):1461–2. (In Chinese).

    Google Scholar 

  28. Chen SX. Enalapril and tanshinone on acute exacerbation of clinical curative effect and prognosis of patients with pulmonary heart disease. Mod Diagn Treat. 2015;26(17):3843–5. (In Chinese).

    CAS  Google Scholar 

  29. Liang ZC. The effect of enalapril and tanshinon on hemorheological and cardiac function of patients with acute exacerbation of chronic pulmonary heart disease. Clin J Chin Med. 2016;8(18):114–6. (In Chinese).

    Google Scholar 

  30. Lin JY, Deng YB, Xiao SR, Xu GD, Luo WG, Jiang YJ. An observation of clinical efficacy of combined treatment of enalapril and tanshinon on pulmonary heart disease during acute exacerbation. Chin Youjiang Med J. 2016;44(6):614–7. (In Chinese).

    Google Scholar 

  31. Li SY. Clinical observation of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jiangxi Med J. 2014;49(9):858–60. (In Chinese).

    CAS  Google Scholar 

  32. Liu JL, Shang XX, Wang CB, Tang Y, Yang LC. Investigating the clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. China Health Care Nutr. 2017;27(29):126–7. (In Chinese).

    Google Scholar 

  33. Lu CB, Zhou ZJ. Efficacy and safety of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Chin J Mod Drug Appl. 2014;8(1):181–2. (In Chinese).

    Google Scholar 

  34. Lu P. Clinical observation of adenosine cyclophosphor meglamine combined with tanshinone sodium IIA sulfonate in pulmonary heart disease. J Med Theor Prac. 2017;30(24):3634–6. (In Chinese).

    Google Scholar 

  35. Ma Y. Enalapril combined with tanshinone treatment of pulmonary heart disease in acute exacerbation of observation. Cardiovasc Dis J Integr Tradit Chin Western Med. 2015;3(10):124–5. (In Chinese).

    Google Scholar 

  36. Mei WH. Clinical observation of enalapril combined with tanshinone in acute exacerbation of pulmonary heart disease. Womens Health Res. 2018;5:2. (In Chinese).

    Google Scholar 

  37. Ni F. Clinical study on sodium tanshinone IIA sulfonate combined with phentolamine in the treatment of 55 patients with acute exacerbation phase of pulmonary heart disease. China Pharm. 2018;27(20):44–6. (In Chinese).

    Google Scholar 

  38. Song HH, Deng GS, Li G. Analysis of improvement of enalapril and tanshinone for blood rheology and cardiac function in patients with acute exacerbation of pulmonary heart disease. J Clin Pulm Med. 2017;22(6):1078–81. (In Chinese).

    Google Scholar 

  39. Wang W. Clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of cor pulmonale. Heilongjiang Med J. 2021;34(3):588–90. (In Chinese).

    Google Scholar 

  40. Wang XQ. Study on the effect of enalapril combined with tanshinone and improvement of cardiac function in patients with acute exacerbation of pulmonary heart disease. Clin Res. 2019;27(3):93–5. (In Chinese).

    Google Scholar 

  41. Wang XR, Zhao S. The effects of tanshinone IIA sulfonate on hemorheology and blood lipid in patients with pulmonary heart disease. Chin J Biochem Pharm. 2011;32(3):237–8. (In Chinese).

    Google Scholar 

  42. Yang YQ. Curative effect of enazepril and tanshinone in treatment of acute exacerbation of chronic pulmonary heart disease. Chin J Exp Tradit Med Formulae. 2012;18(10):292–4. (In Chinese).

    Google Scholar 

  43. Zhang J, He CB, Wang SW. Clinical Observation of sulfotanshinone sodium injection combined with alprostadil and sildenafil in treatment of patients with chronic pulmonary heart disease associated by pulmonary hypertension. Med Pharm J Chin PLA. 2018;30(1):71–3. (In Chinese).

    Google Scholar 

  44. Li JS, Wang HF, Bai YP, Li SY, Yu XQ, Li Y. Ligustrazine injection for chronic pulmonary heart disease: a systematic review and meta-analysis. Evid Based Compl Alt. 2012; 2012: 792726.

  45. Li JS, Wang HF, Li SY, Yu XQ, Wang ZW. Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complem Med. 2011;17(7):579–87.

    Article  Google Scholar 

  46. Guan R, Wang J, Li Z, Ding M, Li D, Xu G, Wang T, Chen Y, Yang Q, Long Z, Cai Z, Zhang C, Liang X, Dong L, Zhao L, Zhang H, Sun D, Lu W. Sodium tanshinone IIA sulfonate decreases cigarette smoke-induced inflammation and oxidative stress via blocking the activation of MAPK/HIF-1alpha signaling pathway. Front Pharmacol. 2018;9:263.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chen PX, Zhang YL, Xu JW, Yu MH, Huang JH, Zhao L, Zhou WL. Sodium tanshinone IIA sulfonate stimulated Cl– secretion in mouse trachea. PLoS ONE. 2017;12(5):e0178226.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by China Postdoctoral Science Foundation (2021M690559), Natural Science Foundation of Sichuan Province (2022NSFSC1327), Young Talents Project of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital (2021QN07), Science and technology project of Sichuan Provincial Health Commission (23LCYJ018), Sichuan Province Cadres Health Research Project (2023 − 213), Scientific and Technological Project of Shiyan City of Hubei Province (21Y78), Guangdong Basic and Applied Basic Research Foundation (2020A1515110867) and Medical Scientific Research Foundation of Guangdong Province of China (A2021416).

Author information

Author notes

  1. Huikai Shao, Fei Yu, and Dongsheng Xu contributed equally to this work.

Authors and Affiliations

  1. Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China

    Huikai Shao & Rongsheng Tong

  2. Sinopharm Dongfeng General Hospital, Hubei University of Medicine, 442008, Shiyan, China

    Fei Yu

  3. Institute of Pharmaceutical Analysis, College of Pharmacy, Jinan University, Guangzhou, 510006, China

    Dongsheng Xu

  4. TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China

    Chunyan Fang

  5. Center for Disease Prevention and Control of Baoan District, Shenzhen, 518101, China

    Lingguo Zhao

Authors
  1. Huikai Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongsheng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chunyan Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rongsheng Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lingguo Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Huikai Shao: Design, conception, searching literatures, extracting data, evaluating quality, performing statistical analysis, interpreting data, drafting and revising manuscript. Fei Yu: Design, conception, performing statistical analysis, interpreting data, drafting and revising manuscript. Dongsheng Xu: Searching literatures, extracting data, evaluating quality, performing statistical analysis, interpreting data, drafting manuscript. Chunyan Fang: Design, conception, performing statistical analysis, interpreting data, drafting and revising manuscript. Rongsheng Tong: Design, conception, performing statistical analysis, interpreting data, drafting and revising manuscript. Lingguo Zhao: Design, conception, performing statistical analysis, interpreting data, drafting and revising manuscript. All authors approved the final version of the manuscript. All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.

Corresponding authors

Correspondence to Chunyan Fang, Rongsheng Tong or Lingguo Zhao.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shao, H., Yu, F., Xu, D. et al. A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease. BMC Complement Med Ther 24, 151 (2024). https://doi.org/10.1186/s12906-024-04434-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-024-04434-0

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us